UroGen Pharma (NASDAQ:URGN) Posts Quarterly Earnings Results, Beats Expectations By $0.29 EPS

UroGen Pharma (NASDAQ:URGN) issued its quarterly earnings results on Wednesday. The company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.29, RTT News reports. The firm had revenue of $25.20 million for the quarter, compared to analysts’ expectations of $24.22 million. During the same quarter in the previous year, the firm posted ($0.68) earnings per share.

UroGen Pharma Stock Down 1.1 %

UroGen Pharma stock opened at $12.10 on Friday. UroGen Pharma has a twelve month low of $10.60 and a twelve month high of $20.70. The stock has a 50 day moving average of $12.82 and a two-hundred day moving average of $14.20. The company has a quick ratio of 7.93, a current ratio of 8.15 and a debt-to-equity ratio of 3.23.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on URGN shares. Oppenheimer reaffirmed an “outperform” rating and issued a $40.00 price target on shares of UroGen Pharma in a research note on Wednesday, October 16th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price target on shares of UroGen Pharma in a research note on Tuesday, October 15th. EF Hutton Acquisition Co. I raised UroGen Pharma to a “strong-buy” rating in a research note on Monday, October 14th. Finally, Guggenheim started coverage on UroGen Pharma in a research note on Thursday, August 22nd. They issued a “buy” rating and a $40.00 price target on the stock. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, UroGen Pharma currently has an average rating of “Buy” and a consensus price target of $48.38.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.